To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 288 participants.

Also called NCT02319603

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 288 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02319603
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02319603. Randomized; double masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2017-02 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
To Evaluate the Efficacy and Safety of Wenxin Keli in Treating Atrial Premature Beats
Condition
Atrial Premature Beats
Intervention (Drug)
Low dose WenXin keli
Intervention (Drug)
High dose WenXin keli
Lead sponsor
Beijing Bozhiyin T&S Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct02319603
Content hash
89d900c69d9a004fb2f0c353a0913fc920897401deace5dc062d8da0626f50eb